AMAG Stock Price - AMAG Pharmaceuticals Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Open $24.45
Day Range 23.00 - 24.65
52 Week Range 11.93 - 25.63
Market Cap $849.59M
Shares Outstanding 34.33M
Public Float 33.53M
Beta 1.36
Rev. per Employee $809.49K
P/E Ratio n/a
EPS $-6.20
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 10.14M 05/31/18
% of Float Shorted 30.25%
Average Volume 726.84K

5 Day	-3.82%
1 Month	-5.58%
3 Month	16.96%
YTD	75.66%
1 Year	41.92%

MarketWatch
Other Dow Jones

AMAG Pharmaceuticals downgraded to neutral from buy at Janney

Jun. 15, 2018 at 11:04 a.m. ET
by Tomi Kilgore

Palatin shares surge 9% premarket after FDA accepts for review treatment for HSDD

Palatin Technologies Inc. shares surged 9% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has accepted the new drug application for bremelanotide, a treatment for female sexual desire disorder. The NDA was filed by Amag Pharmaceuticals Inc. , Palatin's exclusive North America licensee, in March. The goal date for completion of the review is March 23, 2019. If approved, bremelanotide would be the first and only treatment for hypoactive sexual desire disorder (HSDD) in pre-menopausal women, that can be taken as desired. The FDA's acceptance has triggered a $20 million milestone payment to Palatin under its agreement with Amag Pharma. Palatin can receive up to $80 million in milestone payments, and is also entitled to received tiered royalties on sales ranging from high single-digit to low double-digit percentages and up to $300 million contingent upon meeting certain sales milestones. HSDD affects about 12 million women in the U.S. Palatin shares have gained 38.6% in 2018 so far, while the S&P 500 has gained 2.3%.

Jun. 4, 2018 at 8:03 a.m. ET
by Ciara Linnane

Palatin shares up 9% premarket

Jun. 4, 2018 at 7:54 a.m. ET
by Ciara Linnane

Palatin, Amag Pharma's treatment for female sexual desire disorder accepted for FDA review

Jun. 4, 2018 at 7:54 a.m. ET
by Ciara Linnane

Stocks close higher for fifth straight session as Dow reclaims 25,000-level

Feb. 15, 2018 at 4:23 p.m. ET
by Sue Chang

Amag Pharmaceuticals upgraded to buy vs. neutral at Janney

Feb. 15, 2018 at 8:24 a.m. ET
by Ciara Linnane

Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector

Feb. 15, 2018 at 7:13 a.m. ET
by Ciara Linnane

Antares Pharma, Amag Pharma shares soar premarket after FDA approves quickshot auto injector

Feb. 15, 2018 at 7:06 a.m. ET
by Ciara Linnane

Health-care ETF tumbles, pressured by pharmaceutical company weakness

Feb. 5, 2018 at 2:12 p.m. ET
by Ryan Vlastelica

Valeant has officially given up its $1 billion bet on the ‘female Viagra’

Nov. 7, 2017 at 7:52 a.m. ET
by Emma Court

15 companies with outsized sales growth and widening profit margins

Apr. 7, 2017 at 8:34 a.m. ET
by Philip van Doorn

AMAG Pharmaceuticals stock surges 4% after closing $50 mln licensing agreement for menopause drug

Apr. 4, 2017 at 8:55 a.m. ET
by Emma Court

AMAG Pharmaceuticals stock surges 4% after closing licensing agreement with Endoceutics

Apr. 4, 2017 at 8:37 a.m. ET
by Emma Court

The best (and worst) small-cap stocks since Donald Trump’s election

Jan. 17, 2017 at 4:44 p.m. ET
by Philip van Doorn

AMAG Pharmaceuticals downgraded to market perform from outperform at Leerink Partners

Jan. 10, 2017 at 7:27 a.m. ET
by Tomi Kilgore

AMAG Pharmaceuticals downgraded toneutral from buy at Janney

Jan. 10, 2017 at 7:27 a.m. ET
by Tomi Kilgore

AMAG Pharmaceuticals downgraded to underperform from market perform at Raymond James

Jan. 9, 2017 at 11:20 a.m. ET
by Tomi Kilgore

AMAG Pharmaceuticals' stock tumbles 24%, leads Nasdaq losers, after Q3 results

Nov. 3, 2015 at 9:41 a.m. ET
by Tomi Kilgore

Biotech glamour stocks continue present opportunity

Mar. 6, 2015 at 3:54 p.m. ET
by Kevin Marder

Premium

S&P, Dow rattle cage on the breakout point

Mar. 4, 2015 at 11:03 a.m. ET
by Michael Ashbaugh

Stocks to Watch: Apple, Amazon, Alphabet, Cisco, Marriott, Applied Materials, Avon, Waste Management

Feb. 15, 2018 at 9:31 a.m. ET
on The Wall Street Journal

Medivation Sets Wednesday as Cutoff for Vote on Sanofi’s Proposal to Remove Board

Jun. 1, 2016 at 7:38 p.m. ET
on The Wall Street Journal

Six Biotechs to Like Right Now

Jan. 26, 2016 at 10:10 a.m. ET
on Barron's

Hillary Clinton Tweet Sends Biotech Stocks Tumbling

Sep. 21, 2015 at 1:29 p.m. ET
on The Wall Street Journal

CFO Moves: MicroStrategy, Keryx Biopharmaceuticals, Energy Focus

Jul. 27, 2015 at 6:25 p.m. ET
on The Wall Street Journal

The Morning Leverage: GTCR Sells Cord Blood Registry for $700 Million

Jun. 30, 2015 at 10:42 a.m. ET
on The Wall Street Journal

Up and Down the Ladder: The Latest Comings and Goings at Alnylam, Valeant and…

Jun. 12, 2015 at 9:01 a.m. ET
on The Wall Street Journal

Stocks to Watch: Abercrombie & Fitch, Avago Technologies, J&J

May. 28, 2015 at 9:33 a.m. ET
on The Wall Street Journal

After Departures, Perella Aims to Rebuild

Apr. 8, 2015 at 3:33 p.m. ET
on The Wall Street Journal

Amazon Starts Email Service for Companies

Jan. 28, 2015 at 5:55 p.m. ET
on The Wall Street Journal

A Buyer’s Guide to Best Computers for Business

Oct. 27, 2014 at 12:42 a.m. ET
on The Wall Street Journal

Stocks to Watch: DreamWorks Animation, Athlon Energy, Tibco Software

Sep. 29, 2014 at 9:31 a.m. ET
on The Wall Street Journal

Lumara Health to Sell Assets to AMAG, Perrigo for $757 Million

Sep. 29, 2014 at 8:19 a.m. ET
on The Wall Street Journal

Up and Down the Ladder: The Latest Comings and Goings at AMAG, Takeda, FDA and…

Sep. 19, 2014 at 8:41 a.m. ET
on The Wall Street Journal

Up and Down the Ladder: The Latest Comings and Goings at Medivir, Adamas and…

Aug. 15, 2014 at 7:57 a.m. ET
on The Wall Street Journal

Up And Down The Ladder.. Job Changes.. Comings and Goings at Amgen, Bristol and..

Jun. 13, 2014 at 9:12 a.m. ET
on The Wall Street Journal

FDA Turns Down Application for Amag's Drug

Jan. 22, 2014 at 9:41 a.m. ET
on The Wall Street Journal

Stocks to Watch: Saks, Zale, Multiband

May. 22, 2013 at 8:59 a.m. ET
on The Wall Street Journal

Stocks to Watch: Facebook, Synnex, Watson Pharma

Jun. 26, 2012 at 9:22 a.m. ET
on The Wall Street Journal

Stocks to Watch: Cisco Systems, Avon Products, Kohl's

May. 10, 2012 at 10:01 a.m. ET
on The Wall Street Journal

Other News
Press Releases

AMAG to divest Cord Blood Registry for $530M

Jun. 15, 2018 at 7:15 a.m. ET
on Seeking Alpha

Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Jun. 7, 2018 at 6:58 a.m. ET
on benzinga.com

Tricida readies IPO

Jun. 5, 2018 at 1:33 p.m. ET
on Seeking Alpha

Amag Pharmaceuticals Receives a Hold from Cantor Fitzgerald

Cantor Fitzgerald analyst William Tanner reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG) yesterday ...[...]

Jun. 4, 2018 at 9:34 p.m. ET
on SmarterAnalyst

Brandes Investment's Top 7 Positions in the 1st Quarter

Jun. 4, 2018 at 5:44 p.m. ET
on GuruFocus.com

Antares Pharma, Excellent Risk-Reward Profile

May. 22, 2018 at 2:26 p.m. ET
on Seeking Alpha

Top Analyst Upgrades and Downgrades: Applied Materials, Campbell Soup, Ceridien HCM, Dillard’s, Energizer, nLIGHT, Snap, Turtle Beach and More

The top analyst upgrades, downgrades and other research calls from Monday include Applied Materials, Campbell Soup, Ceridien HCM, Dillard's, Energizer, nLIGHT, Snap, Turtle Beach

May. 21, 2018 at 8:55 a.m. ET
on 247WallSt.com

Premarket analyst action - healthcare

May. 21, 2018 at 8:19 a.m. ET
on Seeking Alpha

Institutional Top Ideas Series: Opaleye Management

May. 17, 2018 at 1:52 a.m. ET
on Seeking Alpha

Broadfin Capital, LLC Buys Adamas Pharmaceuticals Inc, La Jolla Pharmaceutical Co, AMAG ...

Broadfin Capital, LLC Buys Adamas Pharmaceuticals Inc, La Jolla Pharmaceutical Co, AMAG Pharmaceuticals Inc, Sells Ignyta Inc, Endo International PLC, Mirati Therapeutics Inc

May. 14, 2018 at 7:38 p.m. ET
on GuruFocus.com

AMAG Pharmaceuticals (AMAG) Presents At 43rd Annual Deutsche Bank Healthcare Conference - Slideshow

May. 10, 2018 at 2:23 p.m. ET
on Seeking Alpha

10-Q: AMAG PHARMACEUTICALS INC.

May. 4, 2018 at 4:23 p.m. ET
on Edgar Online - (EDG = 10Q, 10K)

AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View

AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.

May. 4, 2018 at 2:17 p.m. ET
on Zacks.com

AMAG Pharmaceuticals' (AMAG) CEO William Heiden on Q1 2018 Results - Earnings Call Transcript

May. 3, 2018 at 2:36 p.m. ET
on Seeking Alpha

AMAG Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides

May. 3, 2018 at 2:18 p.m. ET
on Seeking Alpha

Amag Pharmaceuticals Receives a Hold from Cantor Fitzgerald

Cantor Fitzgerald analyst William Tanner reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG) today ...[...]

May. 3, 2018 at 1:53 p.m. ET
on SmarterAnalyst

Notable earnings before Thursday’s open

May. 2, 2018 at 5:30 p.m. ET
on Seeking Alpha

Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.

May. 1, 2018 at 10:18 a.m. ET
on Zacks.com

Reader Inquiry: Antares Pharma PDUFA Date In September, Is Stock A Buy Here?

Apr. 9, 2018 at 9:31 p.m. ET
on Seeking Alpha

By The Numbers: Best Biotech Stocks

Apr. 5, 2018 at 6:47 a.m. ET
on Seeking Alpha

California Cryobank And Cord Blood Registry To Be Combined By GI Partners To Create A Leading Life Sciences Platform

Jun. 15, 2018 at 7:10 a.m. ET
on PR Newswire - PRF

AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry(R)

Jun. 15, 2018 at 7:01 a.m. ET
on GlobeNewswire

Initiating Free Research Reports on ArQule and Three Other Biotech Equities

Jun. 13, 2018 at 7:27 a.m. ET
on ACCESSWIRE

AMAG Pharmaceuticals, Inc. and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies

Jun. 11, 2018 at 4:45 p.m. ET
on GlobeNewswire

Global Imaging Agents Industry

Jun. 11, 2018 at 2:46 p.m. ET
on PR Newswire - PRF

Contrast Agents Market is Determined to Cross US$ 5.65 Billion By 2022

Jun. 8, 2018 at 11:13 a.m. ET
on Heraldkeeper

AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide

Jun. 4, 2018 at 7:01 a.m. ET
on GlobeNewswire

Contrast Agents Market is Supposed to Reach US$ 5.65 Billion By 2022

May. 30, 2018 at 2:28 p.m. ET
on Heraldkeeper

CA 125 Test Market Latest Industry Scenario, Trends, Share & Future Forecast 2017 - 2023

May. 21, 2018 at 1:37 p.m. ET
on Heraldkeeper

Nanotechnology in Medical Devices Market Share, Size & Research Report 2018-2021

May. 18, 2018 at 2:47 a.m. ET
on Heraldkeeper

AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause

May. 9, 2018 at 7:01 a.m. ET
on GlobeNewswire

AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance

May. 3, 2018 at 7:01 a.m. ET
on GlobeNewswire

AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer

May. 2, 2018 at 8:01 a.m. ET
on GlobeNewswire

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

Apr. 27, 2018 at 8:01 a.m. ET
on GlobeNewswire

AMAG Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 3, 2018 at 8:00 a.m. ET

Apr. 26, 2018 at 8:01 a.m. ET
on GlobeNewswire

CA 125 Test Market will Increase to Grow at a CAGR of 5.7 % By 2023

Apr. 24, 2018 at 5:59 a.m. ET
on Financeswire

Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes, AMAG Pharmaceuticals, Intersect ENT, and First Financial -- Discovering Underlying Factors of Influence

Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes, AMAG Pharmaceuticals, Intersect ENT, and First Financial -- Discovering Underlying Factors of Influence

Apr. 24, 2018 at 3:53 a.m. ET
on GlobeNewswire

CA 125 Test Market is Expected to Grow at a CAGR of 5.7 % By 2023

Apr. 16, 2018 at 7:20 a.m. ET
on Heraldkeeper

Contrast Agents Market is Forecast to Cross US$ 5.65 Billion By 2022

Apr. 12, 2018 at 12:15 p.m. ET
on Financeswire

AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

Mar. 26, 2018 at 8:01 a.m. ET
on GlobeNewswire

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases.Its products include Intrarosa, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 10 Full Ratings

HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold

Apr. 6, 2018 at 2:44 p.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For February 15, 2018

Feb. 15, 2018 at 10:24 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For October 23, 2017

Oct. 23, 2017 at 9:19 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Rockwell Medical Inc.	-1.90%	$272.82M
Akorn Inc.	1.60%	$1.88B
Hologic Inc.	0.17%	$10.98B
Keryx Biopharmaceuticals Inc.	0.40%	$608.66M
AmerisourceBergen Corp.	0.47%	$20.52B

Competitor Data Provided By

Dow	24,938.61	-236.70	-0.94%
S&P 500	2,769.29	-13.20	-0.47%
Nasdaq	7,729.16	-31.88	-0.41%
GlobalDow	3,037.88	-26.48	-0.86%
Gold	1,281.10	-27.20	-2.08%
Oil	64.73	-2.16	-3.23%

AMAG Pharmaceuticals Inc.

$ 23.28

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

AMAG Pharmaceuticals downgraded to neutral from buy at Janney

Palatin shares up 9% premarket

Palatin, Amag Pharma's treatment for female sexual desire disorder accepted for FDA review

Amag Pharmaceuticals upgraded to buy vs. neutral at Janney

Antares Pharma, Amag Pharma shares soar premarket after FDA approves quickshot auto injector

AMAG Pharmaceuticals stock surges 4% after closing licensing agreement with Endoceutics

AMAG Pharmaceuticals downgraded to market perform from outperform at Leerink Partners

AMAG Pharmaceuticals downgraded toneutral from buy at Janney

AMAG Pharmaceuticals downgraded to underperform from market perform at Raymond James

AMAG Pharmaceuticals' stock tumbles 24%, leads Nasdaq losers, after Q3 results

Stocks

Columns

Authors

Topics

^$ 23.28